0T20 Stock Chart & Stats
€6.60
€0.00(0.00%)
At close: 4:00 PM EDT
€6.60
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€6.40 - €6.60
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.94M
Enterprise Value€16.35
Total Cash (Recent Filing)€3.13M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Aug 06, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding15,228,328
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-14.78
Price to Sales (P/S)3.33
P/FCF Ratio-0.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.87Price Target Upside-86.84% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-1.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Capital StructureHaving no debt materially reduces near-term solvency and refinancing risk for a clinical-stage biotech that relies on intermittent capital raises. Long-term, a debt-free capital structure preserves operational flexibility to prioritize R&D spend and negotiate non-dilutive funding without fixed interest burdens.
Broad-spectrum Antiviral Portfolio & PartnershipsTraws' focus on broad-spectrum antivirals and active partnerships with public health agencies builds durable strategic differentiation in pandemic preparedness markets. Local manufacturing plans and regulatory collaboration in Africa support sustained access, potential stockpiling contracts, and longer-term commercial channels beyond single-drug outcomes.
Established Access To Equity FinancingConfirmed PIPE proceeds and an active ATM/shelf program provide repeatable access to capital to fund clinical programs. For a loss-making biotech, durable lines of equity financing extend runway to achieve clinical inflection points, reducing the immediate existential funding risk while enabling milestone-driven development.
Bears Say
Negative EquityNegative shareholders' equity signals cumulative operating losses or write-downs that have eroded the capital base. This structural weakness limits financial flexibility, constrains ability to borrow non-dilutive capital, can complicate grant/partnership negotiations, and raises the probability of future dilutive financings.
Consistent Negative Operating Cash FlowPersistent operating cash burn without positive free cash flow forces reliance on external funding to sustain R&D and trials. Over multiple periods this reduces strategic optionality, increases dilution risk, and creates execution risk if financing windows close before clinical milestones are reached.
Regulatory And Clinical Execution SetbacksDeferral of the Phase 2a influenza challenge trial following a negative MHRA review (and concurrent U.S. IND clinical hold referenced elsewhere in filings) lengthens timelines, raises incremental preclinical/toxicology costs, and increases the probability that key commercial milestones slip or require additional capital to resolve.
Traws Pharma News
0T20 FAQ
What was Traws Pharma’s price range in the past 12 months?
Traws Pharma lowest stock price was €6.40 and its highest was €6.60 in the past 12 months.
What is Traws Pharma’s market cap?
Traws Pharma’s market cap is €5.94M.
When is Traws Pharma’s upcoming earnings report date?
Traws Pharma’s upcoming earnings report date is Aug 06, 2026 which is in 3 days.
How were Traws Pharma’s earnings last quarter?
Traws Pharma released its earnings results on May 15, 2026. The company reported -€0.46 earnings per share for the quarter, beating the consensus estimate of -€0.486 by €0.026.
Is Traws Pharma overvalued?
According to Wall Street analysts Traws Pharma’s price is currently Overvalued.
Does Traws Pharma pay dividends?
Traws Pharma does not currently pay dividends.
What is Traws Pharma’s EPS estimate?
Traws Pharma’s EPS estimate is -0.29.
How many shares outstanding does Traws Pharma have?
Traws Pharma has 15,228,328 shares outstanding.
What happened to Traws Pharma’s price movement after its last earnings report?
Traws Pharma reported an EPS of -€0.46 in its last earnings report, beating expectations of -€0.486. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Traws Pharma?
Currently, no hedge funds are holding shares in DE:0T20
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Traws Pharma
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
0T20 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced meaningful scientific and financing progress against important regulatory and liquidity risks. Positives include a $60M contingent financing package, robust preclinical data, a next-gen tablet with ~30% higher exposure supporting once-monthly prophylaxis, an approved Australian bridging study and plans for a U.K. human challenge trial. Key negatives are a low year-end cash balance ($3.8M), an FDA clinical hold on the IND for toxicology concerns that could materially delay U.S. development, and dependence on milestone warrants and one-time accounting items for near-term financial stability. Overall, the update conveys cautious optimism but highlights significant execution and regulatory risks that must be resolved to fully realize the program’s potential.View all DE:0T20 earnings summaries0T20 Stock 12 Month Forecast
Average Price Target
€0.87
▼(-86.84% Downside)